United States-based CONTINUUS Pharmaceuticals Inc announced on Thursday that it has received a USD69.3m United States government contract to facilitate domestic production of three vital medicines intended to treat critically ill patients, including those with COVID-19.
The Department of Defense (DoD) awarded the contract in collaboration with the Department of Health and Human Services (HHS).
The contract will also allow construction of the country's first Good Manufacturing Practices (GMP)-certified facility for end-to-end, ICM-driven production of small-molecule drugs, including marketed products, generic medications and investigational therapies through all phases of clinical trials and a product's lifecycle. CONTINUUS Pharmaceuticals is also breaking ground for a new facility in Woburn, Massachusetts and aims to make the facility completely operational within two years.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US